-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 31, Wanchun Pharmaceutical announced to submit to the US Food and Drug Administration and the China Medical Products Administration the first Chinese and US new drug listing application for the original innovative drug prinabulin.
Pranabrin has a unique mechanism of action on dendritic cell (DC cell) maturation, antigen presentation and T cell activation.
It is worth mentioning that in the second half of 2020, the National Food and Drug Administration (NMPA) of China and the US FDA respectively granted pranablin the "breakthrough treatment variety" and "breakthrough therapy designation" for the treatment of CIN.